Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study

Archive ouverte

Quantin, Catherine | Yamdjieu Ngadeu, C. | Cottenet, Jonathan | Escolano, Sylvie | Bechraoui-Quantin, Sonia | Rozenberg, Patrick | Tubert-Bitter, Pascale | Gouyon, Jean-Bernard

Edité par CCSD ; Wiley -

International audience. Objective: To assess the risk of preterm birth associated with nonsteroidal anti-inflammatory drugs (NSAIDs), focusing on early exposure in the period from conception to 22 weeks of gestation (WG).Design: National population-based retrospective cohort study.Setting: The French National Health Insurance Database that includes hospital discharge data and health claims data.Population: Singleton pregnancies (2012–2014) with a live birth occurring after 22WG from women between 15 and 45 years old and insured the year before the first day of gestation and during pregnancy were included. We excluded pregnancies for which anti-inflammatory medications were dispensed after 22WG.Methods: The association between exposure and risk of preterm birth was evaluated with GEE models, adjusting on a large number of covariables, socio-demographic variables, maternal comorbidities, prescription drugs and pregnancy complications.Main outcome measures: Prematurity, defined as a birth that occurred before 37WG.Results: Among our 1 598 330 singleton pregnancies, early exposure to non-selective NSAIDs was associated with a significantly increased risk of preterm birth, regardless of the severity of prematurity: adjusted odds ratio (aOR) = 1.76 (95% CI 1.54–2.00) for extreme prematurity (95% CI 22–27WG), 1.28 (95% CI 1.17–1.40) for moderate prematurity (28–31WG) and 1.08 (95% CI 1.05–1.11) for late prematurity (32–36WG), with non-overlapping confidence intervals. We identified five NSAIDs for which the risk of premature birth was significantly increased: ketoprofen, flurbiprofen, nabumetone, etodolac and indomethacin: for the latter, aOR = 1.92 (95% CI 1.37–2.70) with aOR = 9.33 (95% CI 3.75–23.22) for extreme prematurity.Conclusion: Overall, non-selective NSAID use (delivered outside hospitals) during the first 22WG was found to be associated with an increased risk of prematurity. However, the association differs among NSAIDs. Tweetable abstract: French study for which early exposure to non-selective NSAIDs was associated with increased risk of prematurity.

Suggestions

Du même auteur

Impact of the COVID-19 pandemic on preterm birth and stillbirth: a nationwide, population-based retrospective cohort study

Archive ouverte | Simon, Emmanuel | CCSD

International audience

Impact of SARS-CoV-2 infection on risk of prematurity, birthweight and obstetric complications: A multivariate analysis from a nationwide, population-based retrospective cohort study

Archive ouverte | Simon, Emmanuel | CCSD

International audience. Objective: To determine the impact of maternal coronavirus disease 2019 (COVID-19) on prematurity, birthweight and obstetric complications. Design: Nationwide, population-based retrospective ...

Hospitalisation for non-lethal self-harm and premature mortality in the 3 years following adolescent pregnancy: Population-based nationwide cohort study

Archive ouverte | Goueslard, Karine | CCSD

International audience. Objective: To evaluate the risk of non-lethal self-harm and mortality related to adolescent pregnancy. Design: Nationwide population-based retrospective cohort. Setting: Data were extracted f...

Chargement des enrichissements...